Bolt Biotherapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	11.61	11.7	7.21	10.81	9.24	27.38
Short-Term Investments	11.28	15.8	40.12	91.38	159.64	158.84
Cash & Short-Term Investments	22.89	27.51	47.32	102.19	168.89	186.22
Cash Growth	-41.06%	-41.88%	-53.69%	-39.49%	-9.31%	715.39%
Other Current Assets	2.86	2.76	3.49	3.52	3.86	2.94
Total Current Assets	25.75	30.26	50.81	105.71	172.75	189.16
Net Property, Plant & Equipment	19.61	20.48	24.9	24.08	28.53	30.6
Long-Term Investments	1.02	4.34	22.88	26.41	23.94	85.35
Other Long-Term Assets	1.65	1.68	1.04	3.59	2.59	2.61
Total Assets	48.03	56.75	99.63	159.78	227.81	307.72
Accounts Payable	1.74	1.44	1.51	2.99	3.59	3.57
Accrued Expenses	2.02	3.72	9.08	12.49	15.14	12.38
Current Portion of Leases	2.96	2.83	2.25	2.78	2.39	2.5
Unearned Revenue	0.63	0.45	3.02	2.2	1.99	2.87
Total Current Liabilities	7.34	8.44	15.86	20.46	23.12	21.33
Long-Term Leases	19.35	20.13	22.96	17.44	20.22	21.85
Other Long-Term Liabilities	1.51	1.68	3.62	9.15	12.96	14.42
Total Long-Term Liabilities	20.86	21.81	26.58	26.59	33.18	36.27
Total Liabilities	28.21	30.24	42.43	47.04	56.3	57.6
Additional Paid-in Capital	487.86	487.31	484.5	476.99	467.51	457.43
Accumulated Other Comprehensive Income	-0.01	-0.02	0.1	0.04	-0.92	-0.32
Retained Earnings	-468.02	-460.78	-427.4	-364.29	-295.09	-206.99
Total Common Shareholders' Equity	19.82	26.51	57.2	112.74	171.51	250.12
Shareholders' Equity	19.82	26.51	57.2	112.74	171.51	250.12
Total Liabilities & Equity	48.03	56.75	99.63	159.78	227.81	307.72
Total Debt	22.31	22.96	25.21	20.22	22.61	24.36
Net Cash (Debt)	0.58	4.55	22.11	81.97	146.28	161.86
Net Cash Growth	-87.16%	-79.44%	-73.02%	-43.96%	-9.63%	1253.27%
Net Cash Per Share	0.32	2.43	11.58	43.36	78.31	97.52
Book Value	19.82	26.51	57.2	112.74	171.51	250.12
Book Value Per Share	10.94	14.17	29.96	59.63	91.82	150.69
Tangible Book Value	19.82	26.51	57.2	112.74	171.51	250.12
Tangible Book Value Per Share	10.94	14.17	29.96	59.63	91.82	150.69

SEC Filings: 10-K · 10-Q